A Member of the Cancer Information Network
Cancer Information by State:
  arrow Patient Home   arrow Professional Home   arrow Newsletters   arrow Feedback Survey  
Main Menu
Quick Links
Information by Disease
Cancer News
Conference Coverage
Oncology Stocks
AZN$44.82-0.37 (-0.82%)
NVS$53.13-0.16 (-0.3%)
SNY$37.67-0.01 (-0.03%)
GSK$41.530.06 (0.14%)
click here

Home: Drug Pipeline   Print This Page 


Cancer Consultants Cancer Drug Pipeline



Brain Cancer
Drug Name Class Developer Phase
109881 Taxane Aventis II
1311-TM-601 (chlorotoxin) Scorpian toxin TransMolecular I
Alanosine Antimetabolite Triange II
Alkylade (0-6-benzylguanine) AGT inhibitor Access Oncology, Pacific Pharmaceuticals III
Atrasentan (xinlay) Endothelial receptor agonist Abbott Laboratories II
AV-4551 Vaccine AVI Biopharm I
CC 8490 (benzopyran) SERM Celgene II Glioblastoma
Cereport (lobradimil) Bradykin analog Alkermes III
Cervene (TP 38) Immunotoxin IVAX Corporation II
Cotara Radiolabeled antibody Peregrine Pharmaceuticals II(Glioblastoma)
DC Vax Vaccine Northwest Biotherapeutics II
DTI-015 BCNU in 100% ethynol Direct Therapeutics III Glioblastoma
Efaproxyn Radio sensitizer Allos FDA Submission
EG009 (cerepro) Gene therapy Ark Therapeutics II
G207 Gene therapy MediGene I
IL-13-PE38 Fusion protein Neo Pharm I Glioblastoma
Intereferon Beta Gene Tx Gene therapy Biogen/Idec I
Iressa (gefitinib) EGFR Inhibitor AstraZeneca II
Karenectin (BNP 1350) Camptothecin BioNeumerik II
NBI-3001 IL-4 fusion toxin Neurocrine Biosciences II
Photofrin (porfimer sodium) Photosensitizer QLT Therapeutics III
Reolysin Reovirus Oncolytics I
Sarasar (lonafarnib) Oral Farnesyl Protein Transferase Inhibitor Schering-Plough I
SU101 (leflunomide) PDGFR inhibitor Pfizer III
Tarceva (erlotinib) EGFR tyrosine kinase inhibitor Genentech, Roche II
Temodar (temazolomide) Alkylating agent Schering FDA Approval 03/05
Xcytrin (motexafin) Synthetic Metalloterxaphryn Pharmacyclics II
For more information contact us at clinicaltrials@cancerconsultants.com

View Drugs in Pipeline By Disease



© 1998-2007 CancerConsultants.com  All Rights Reserved.